Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK1 | P04629 | 6/20 | 0.37 |
| ▸ | TNKS | O95271 | 1/20 | 0.36 |
| ▸ | ACVR1 | Q04771 | 3/20 | 0.36 |
| ▸ | CNR2 | P34972 | 2/20 | 0.36 |
| ▸ | PLK4 | O00444 | 2/20 | 0.35 |
| ▸ | FLT3 | P36888 | 2/20 | 0.35 |
| ▸ | PIM1 | P11309 | 2/20 | 0.34 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.34 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.34 |
| ▸ | AURKA | O14965 | 2/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | KDR | P35968 | 1/20 | 0.33 |
| ▸ | ETV6 | P41212 | 1/20 | 0.33 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24418437 | 0.91 | NTRK1 (0.40) | NTRK1TNKSACVR1CNR2PLK4 | |
| SCHEMBL24418315 | 0.90 | TNKS (0.46) | TNKSACVR1PLK4FLT3AURKA | |
| SCHEMBL29606913 | 0.90 | TNKS (0.46) | TNKSACVR1PLK4FLT3AURKA | |
| SCHEMBL24418445 | 0.89 | LRRK2 (0.38) | NTRK1TNKSACVR1PLK4FLT3 | |
| SCHEMBL26351325 | 0.88 | AURKA (0.44) | NTRK1TNKSACVR1PLK4FLT3 | |
| SCHEMBL24418646 | 0.88 | TLR9 (0.41) | NTRK1TNKSACVR1PLK4FLT3 | |
| SCHEMBL24418379 | 0.87 | WNT3A (0.42) | NTRK1TNKSACVR1PIM1MAPK1 | |
| SCHEMBL24418443 | 0.86 | JAK2 (0.38) | NTRK1TNKSACVR1CNR2PLK4 | |
| SCHEMBL24418647 | 0.86 | FGFR2 (0.38) | NTRK1TNKSACVR1PLK4FLT3 | |
| SCHEMBL24418383 | 0.85 | PIM1 (0.39) | NTRK1TNKSACVR1CNR2PLK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230322789-A1 | PYRAZOLOPYRIDAZINONE COMPOUND, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | BROADENBIO CO., LTD. (CN) | 2023-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230322789-A1 | PYRAZOLOPYRIDAZINONE COMPOUND, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | PDXK, CMPK1, GCK | NTRK1 1243/4885TNKS 200/4885ACVR1 2808/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.